Key result
The angiotensinogen 235 TT genotype predicted the nonmodulating hypertensive phenotype, with odds increasing to 5.36 when combined with ACE DD and CYP11B2 -344 TT.
Why the study?
Can genotyping of renin-angiotensin-aldosterone system genes predict the nonmodulating intermediate phenotype in subjects with essential hypertension?
Observational (n=298)
Can genotyping of renin-angiotensin-aldosterone system genes predict the nonmodulating intermediate phenotype in subjects with essential hypertension?
Specific combinations of renin-angiotensin-aldosterone system gene polymorphisms can accurately identify the nonmodulating phenotype in essential hypertension, potentially substituting for complex phenotyping to guide therapy.
Answers are grounded in this paper and cite their sources.
Genotyping RAAS variants was associated with nonmodulating hypertension; leaves open substitution for phenotyping to guide therapy.
We sought to determine whether genes of the renin-angiotensin-aldosterone system can predict the nonmodulating intermediate phenotype in essential hypertension. Aldosterone responses to angiotensin II were assessed in 298 subjects with hypertension. Subjects were genotyped at the angiotensinogen M235T, angiotensin-converting enzyme I/D, aldosterone synthase C-344 T, renin, angiotensin II type 1 receptor, and adducin loci. The data were analyzed by Student t test, ANOVA, stepwise linear regression and general linear model or GENMOD regression techniques, and chi2 analysis odds ratios (ORs). Aldosterone response varied by genotype for angiotensin and aldosterone synthase but not for the other loci. The combination of angiotensinogen 235 TT and angiotensin-converting enzyme DD showed further reduction (P=0.0377) when compared with angiotensinogen 235 TT alone, an example of genetic epistasis. When the subject was required also to possess the CYP11B2 -344 TT genotype, there was a further substantial reduction. Of these 3 loci, only angiotensinogen 235 TT significantly increased the OR of predicting the nonmodulating hypertensive phenotype (OR, 2.00; 95% confidence interval, 1.152 to 3.51). However, when angiotensin-converting enzyme DD was combined with angiotensinogen 235 TT, the OR nearly doubled to 3.74, with a further increase to 5.36-fold when the subject possessed all 3 genotypes. Thus, the angiotensinogen, angiotensin-converting enzyme, and aldosterone synthase genotypes identified individuals with the nonmodulating phenotype with an increasing degree of fidelity. For this subclass of essential hypertension, it is likely that genotyping can be substituted for complex phenotyping for therapeutic and preventive decision making.
No takes yet. Share an insight, caveat, or question.
Kosachunhanun et al. (2003) conducted an observational in Hypertension (n=298). Angiotensinogen 235 TT genotype vs. Other genotypes was evaluated on Nonmodulating hypertensive phenotype (OR 2.00, 95% CI 1.152-3.51). The angiotensinogen 235 TT genotype predicted the nonmodulating hypertensive phenotype, with odds increasing to 5.36 when combined with ACE DD and CYP11B2 -344 TT.
Synapse has enriched 10 related papers. Consider them for comparative context: